MD Anderson Shares Latest Research Breakthroughs
Inflammation may be responsible for driving earliest stages of lung cancer.
Five research highlights from MD Anderson Cancer Center: bacterial DNA in brain tumors, inflammatory drivers of early lung cancer, HSP90 masking BRCA1 mutation effects in breast cancer, a POLE mutation predicting immunotherapy response in colorectal cancer, and other discoveries.
Early‐stage lung cancer often develops in areas of high inflammation; identifying inflammatory drivers such as IL‑1B offers a potential early‑intervention strategy.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT